Online Program

Quantifying the Prescription Drug Insurance Coverage Population During a Pandemic Influenza Event

Tuesday, November 3, 2015

Morgan Mathews, Strategy & Operations, Deloitte Consulting, Atlanta, GA
The intent of this policy-based research was to increase the body of knowledge which informed the Centers for Disease Control and Prevention’s (CDC) public health understanding of the underinsured and uninsured population that may have limited access to antiviral drugs during a pandemic due to product costs and fees associated with prescription drug dispensing when drugs are provided through pharmacies in the United States. A quantitative analysis was conducted to evaluate the state-by-state levels of health insurance coverage for individuals that are classified as Medicare, Medicaid, uninsured, and underinsured, by reviewing policy briefs from the Kaiser Foundation, the Office of the Assistant Secretary for Planning and Evaluation, and the Centers for Medicare and Medicaid Services. Various figures and tables were produced that provided findings for the vulnerable population groups and the costs associated with the antiviral drugs, Tamiflu and Relenza, without insurance coverage. Our research concluded that quantifying the insurance coverage population can effectively drive improvements in public health’s response during a pandemic influenza event.

Learning Areas:

Program planning
Public health or related public policy
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
Evaluate the public health implications around quantifying the prescription drug insurance coverage population during a pandemic influenza event.

Keyword(s): Accessibility, Low-Income

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: As a prior student at Howard University I have been a lead presenter on many research papers within our Health Management department. I have also conducted two public health independent-study project abroad in both Cameroon and Honduras on sustainable living practices and the public vs. private healthcare sector in underdeveloped countries. Lastly, this summer as an intern within CDC's Division of Strategic National Stockpile, I collaborated with the Science team to produce a white paper.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.